US 10,376,589 B2
Method for the treatment of a solid tumour
Brian Stanley Hawkett, Mona Vale (AU); Trevor William Hambley, Ashbury (AU); Nicole Sarah Bryce, Glenbrook (AU); Thi Thuy Binh Pham, Earlwood (AU); and Nirmesh Jain, Parramatta (AU)
Assigned to The University of Sydney, Sydney (AU)
Filed by The University of Sydney, Sydney (AU)
Filed on Dec. 22, 2017, as Appl. No. 15/853,069.
Application 15/853,069 is a continuation of application No. 14/112,673, abandoned, previously published as PCT/AU2012/000414, filed on Apr. 20, 2012.
Claims priority of provisional application 61/477,382, filed on Apr. 20, 2011.
Claims priority of application No. 2011901495 (AU), filed on Apr. 20, 2011; and application No. 2012900480 (AU), filed on Feb. 9, 2012.
Prior Publication US 2018/0117160 A1, May 3, 2018
Int. Cl. A61K 9/00 (2006.01); A61K 47/34 (2017.01); A61K 33/00 (2006.01); A61K 33/24 (2019.01); A61K 45/06 (2006.01); B82Y 5/00 (2011.01); A61K 31/136 (2006.01); A61K 31/337 (2006.01); A61K 31/513 (2006.01); A61K 31/704 (2006.01); A61K 47/02 (2006.01); A61K 51/12 (2006.01)
CPC A61K 47/34 (2013.01) [A61K 31/136 (2013.01); A61K 31/337 (2013.01); A61K 31/513 (2013.01); A61K 31/704 (2013.01); A61K 33/00 (2013.01); A61K 33/24 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01); A61K 51/1244 (2013.01); B82Y 5/00 (2013.01); A61K 9/0019 (2013.01)] 7 Claims
OG exemplary drawing
 
1. A method of treating a solid tumour in a subject, said method comprising co-administering to said subject an effective amount of a non-cytotoxic particulate material and a cellular toxin effective to penetrate said solid tumor and induce cytotoxicity, wherein:
(i) said non-cytotoxic particulate material is administered in the form of a dispersion in a liquid carrier, the non-cytotoxic particulate material being maintained in the dispersed state by a steric stabiliser;
(ii) wherein said steric stabiliser comprises an anchoring portion and a steric stabilising polymeric segment;
(iii) wherein the anchoring portion anchors the steric stabiliser to the non-cytotoxic particulate material, is different from the remainder of the steric stabiliser and has an affinity towards the surface of the particulate material and secures the steric stabiliser to the non-cytotoxic particulate material;
(iv) wherein the cellular toxin is not attached to the non-cytotoxic particulate material; and
(v) wherein the non-cytotoxic particulate material and cellular toxin are co-administered in two separate formulations.